{"id":"NCT03761784","sponsor":"Sol-Gel Technologies, Ltd.","briefTitle":"A Study of S6G5T-3 in the Treatment of Acne Vulgaris","officialTitle":"A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S6G5T-3 in the Treatment of Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-21","primaryCompletion":"2019-12-31","completion":"2019-12-31","firstPosted":"2018-12-03","resultsPosted":"2021-12-01","lastUpdate":"2021-12-16"},"enrollment":424,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"S6G5T-3","otherNames":["Encapsulated Benzoyl Peroxide (E-BPO) and Encapsulated Tretinoin (E-ATRA) Cream, (E-BPO/E-ATRA Cream)"]},{"type":"DRUG","name":"S6G5T-8","otherNames":["Vehicle"]}],"arms":[{"label":"S6G5T-3","type":"EXPERIMENTAL"},{"label":"S6G5T-8 Vehicle Cream","type":"PLACEBO_COMPARATOR"}],"summary":"To assess the efficacy of S6G5T-3 compared to its Vehicle when applied once daily for 12 weeks in participants with acne vulgaris.","primaryOutcome":{"measure":"Percentage of Participants Achieving an IGA Score of Clear or Almost Clear and a Score â‰¥2 Grades Less Than Baseline","timeFrame":"Baseline through Week 12","effectByArm":[{"arm":"S6G5T-3","deltaMin":38.5,"sd":null},{"arm":"S6G5T-8 Vehicle Cream","deltaMin":11.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":274},"commonTop":["Application site pain","Application site dryness","Application site erythema","Application site exfoliation","Upper respiratory tract infection"]}}